Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500696 | 0.94 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL20323008 | 0.94 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21500729 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL20322996 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL20323006 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21500741 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21500694 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21500726 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21500699 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL20322988 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840540-B2 | Dimers of covalent NFKB inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840540-B2 | Dimers of covalent NFKB inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-12-12 | — | — | US | disclosed |
| US-20220009941-A1 | Dimers of Covalent NFKB Inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-01-13 | — | — | US | disclosed |
| US-20190322680-A1 | Dimers of Covalent NFKB Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| WO-2018119177-A1 | DIMERS OF COVALENT NFKB INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009941-A1 | Dimers of Covalent NFKB Inhibitors | NFKBIA, IKBKB, NFKB2 | LMNA 2394/4885SMN1; SMN2 2959/4885ALDH1A1 3908/4885 |
| US-11840540-B2 | Dimers of covalent NFKB inhibitors | NFKBIA, IKBKB, NFKB2 | LMNA 2394/4885SMN1; SMN2 2959/4885ALDH1A1 3908/4885 |
| US-20190322680-A1 | Dimers of Covalent NFKB Inhibitors | NFKBIA, IKBKB, NFKB2 | LMNA 1941/4885SMN1; SMN2 2792/4885ALDH1A1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.